ACRAL ERYTHEMA CAUSED BY HIGH-DOSE METHOTREXATE THERAPY IN PATIENTS WITH OSTEOGENIC SARCOMA

2005 ◽  
Vol 22 (2) ◽  
pp. 167-173 ◽  
Author(s):  
Sergey Postovsky ◽  
Myriam Weyl Ben Arush
1986 ◽  
Vol 32 (3) ◽  
pp. 516-523
Author(s):  
Hiroki GOTOH ◽  
Makoto YOSHIYA ◽  
Osamu OHSHIMA ◽  
Kazuyuki OHTSUKA ◽  
Yohichi KURACHI ◽  
...  

1986 ◽  
Vol 32 (3) ◽  
pp. 524-529
Author(s):  
Masahiro SUMI ◽  
Nobuyoshi KANENIWA ◽  
Makoto YOSHIYA ◽  
Hiroki GOTOH ◽  
Toshikazu TOKUOKA ◽  
...  

Rheumatology ◽  
1988 ◽  
Vol 27 (2) ◽  
pp. 160-162 ◽  
Author(s):  
E. EECKHOUT ◽  
E. SUYS ◽  
P. BUYDENS ◽  
S. VAN BELLE ◽  
L. A. VERBRUGGEN

2008 ◽  
Vol 30 (12) ◽  
pp. 950-952 ◽  
Author(s):  
Theodore Scott Nowicki ◽  
Kari Bjornard ◽  
David Kudlowitz ◽  
Claudio Sandoval ◽  
Somasundaram Jayabose

1995 ◽  
Vol 24 (2) ◽  
pp. 137-140 ◽  
Author(s):  
Zakiya Al-Lamki ◽  
Eileen Thomas ◽  
Nagwa El-Banna ◽  
Norman Jaffe

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Darragh O'Donoghue ◽  
Heather Truong ◽  
Heidi Finnes ◽  
Jennifer McDonald ◽  
Nelson Leung

Abstract Background and Aims High dose Methotrexate (HDMTX) is an important component of several modern oncological/haematological treatment protocols due to its central nervous system penetrance. Nephrotoxicity represents a significant adverse effect and can limit therapeutic options. Therefore, strategies to prevent this are paramount. Urinary alkalinisation and large volume resuscitation to maintain adequate hydration and urine output are the typical strategies. Urinary alkalinisation prevents tubular precipitation of methotrexate and therefore, a strict urinary pH target of 7 is maintained via a continuous bicarbonate infusion. Method We describe a case report, of Iatrogenic metabolic alkalosis leading to respiratory compromise in a patient receiving HDMTX from Mayo Clinic, Rochester. Results We present the case of a 76-year-old woman with a Diffuse Large B-Cell Lymphoma with CNS involvement who presented for elective admission for her 1st cycle of HDMTX. She received 7g of Methotrexate at dosing of 8 g/m2. She received the standard urinary alkalinisation with pre- and post-hydration. Her baseline HCO3- was 28 mEq/L. Her 48 hour MTX level was elevated at 1.2 so the urinary alkalinisation protocol was continued until <0.1 mcmol/L. On day 4, she developed frequent episodes of apnoea. Her ABG demonstrated a metabolic alkalaemia pH 7.54, pCO 53, pO2 91, HCO3 45. She was transferred to the ICU for close monitoring. Her bicarbonate infusion was discontinued and she received acetazolamide. Her bicarbonate improved to 31 after 12 hours. She had a significant improvement in her respiratory status with no further episodes of apnoea. Her bicarbonate infusion was restarted due to elevated MTX levels. She was discharged home with no further complications. Conclusion Iatrogenic Metabolic alkalosis leading to respiratory compromise represents a rare but important complication of urinary alkalinsation protocols for High-dose Methotrexate therapy.


1983 ◽  
Vol 1 (4) ◽  
pp. 251-254 ◽  
Author(s):  
N Jaffe ◽  
E Smith ◽  
H T Abelson ◽  
E Frei

The number and time to appearance of pulmonary metastases were evaluated in 15 patients with osteogenic sarcoma receiving adjuvant chemotherapy with high-dose methotrexate and doxorubicin (adjuvant group). The results were compared to 33 age- and sex-matched controls (control group). The adjuvant group demonstrated a reduction in the number and a delay in the appearance of the metastases. The median time to development of metastases was 17 mo in the adjuvant group and 7 mo in the control group, and the median number of metastases was 2 and 12, respectively.


1998 ◽  
Vol 44 (9) ◽  
pp. 1987-1989 ◽  
Author(s):  
Anne Berit Guttormsen ◽  
Per Magne Ueland ◽  
Per Eystein Lønning ◽  
Olav Mella ◽  
Helga Refsum

Sign in / Sign up

Export Citation Format

Share Document